The Lymphoma Steering Committee (LYSC) addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in adult lymphoma. Committee activities help foster collaboration between groups and institutions engaged in conducting trials. The LYSC's membership comprises NCTN group representatives, NCI-funded consortia representatives, community oncologists, Specialized Programs of Research Excellence (SPORE) representatives, biostatisticians, patient advocates, subject matter experts, and NCI staff.
Co-Chairs
Stephen Ansell, M.D.
Mayo Clinic
John P. Leonard, M.D.
New York University
Members
Tareq Al baghdadi, M.D.
St. Joseph Mercy Hospital
Carl Allen, M.D., Ph.D.
Baylor College of Medicine
Richard F. Ambinder, M.D., Ph.D.
Johns Hopkins University
Nancy L. Bartlett, M.D.
Washington University School of Medicine
Timothy Fenske, M.D.
Methodist Hospital
Christopher Flowers, M.D., M.S., FASCO
University of Texas M.D. Anderson Cancer Center
Boris Freidlin, Ph.D.
National Cancer Institute
Jonathan Friedberg, M.D.
University of Rochester
Meghan Gutierrez
Lymphoma Research Foundation
Patricia Hernandez
Leukemia & Lymphoma Society
Bradford Hoppe, M.D.
Mayo Clinic
Brad Kahl, M.D.
Washington University School of Medicine
Lale Kostakoglu, M.D.
NYU Langone Medical Center
John Kuruvilla, M.D.
University Health Network
Michael LeBlanc, Ph.D.
Fred Hutchinson Cancer Research Center; University of Washington
Richard Little, M.D.
National Cancer Institute
Peter Martin, M.D.
New York University
Alison Moskowitz, M.D.
Memorial Sloan Kettering Cancer Center
Chelsea Pinnix, M.D.
University of Texas M.D. Anderson Cancer Center
Mei-Yin C. Polley, Ph.D.
University of Chicago
Carlos Almeida Ramos, M.D.
Baylor College of Medicine
Kerry Savage, M.D.
BC Cancer Agency
Anurag K. Singh, M.D.
University Of Kansas Medical Center
Sonali Smith, M.D.
University of Chicago
Diego Villa Restrepo, M.D., M.P.H.
BC Cancer Agency
NCI CCCT Program Director
Elena Schwartz, Ph.D., M.S.
elena.schwartz@nih.gov